DUBLIN, April 26, 2016 /PRNewswire/ -- Allergan (NYSE:
AGN) today announced that its data will be presented during the
annual meeting of the Association for Research in Vision and
Ophthalmology (ARVO) in Seattle,
Washington, May 1-5, 2016.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
This data spans retina, ocular surface and glaucoma
subspecialties and is reflective of Allergan's global leadership
position in eye care.
"Allergan is pleased to be presenting data at ARVO this year.
With more than 60 years of eye care experience and 17 mid-to-late
stage programs in development, Allergan is committed to advancing
research and products for the eye care community," said
David Nicholson, Executive Vice
President and President of Global R&D Brands at Allergan.
The scheduled times (noted in local Pacific Time) of the 18
Allergan presentations, presentation titles and locations at the
Washington State Convention Center
are as follows:
Retina:
- The association between onset of self-reported vision
impairment and nursing home residence in an older US population
- Date and Time: Monday, May 2,
2016, 8:30-10:15 AM
- Room: Main Exhibit Hall
- Categories: Community aspects of Eye Care and
Disease
- Consistency of visual acuity response to anti-VEGF therapy in
diabetic macular edema patients: An analysis of DRCR.net Protocol I
data
- Date and Time: Monday, May 2,
2016, 3:45-4:00 PM
- Room: Tahoma 3
- Categories: Diabetic Macular Edema Treatment
- Real-World Assessment of Dexamethasone Intravitreal Implant in
Diabetic Macular Edema: Interim Analysis from the REINFORCE Study
- Date and Time: Tuesday, May 3,
2016, 8:30-10:15 AM
- Room: Main Exhibit Hall
- Categories: Diabetic Retinopathy and Steroids
- A 12-Month, Open-Label, Multicenter Study to Assess the Safety
and Efficacy of Ozurdex 0.7 mg for the Treatment of Macula Edema
Related to Branch Retinal Vein Occlusion in Korea; the COBALT Study
- Date and Time: Tuesday, May 3,
2016, 3:45-5:30 PM
- Room: Main Exhibit Hall
- Categories: Macular Edema Clinical &
Translational
- Ocular Pharmacokinetics of Brimonidine Drug Delivery System in
Rabbits and Monkeys and Its Application in Selection of Dosing
Frequency in Human Clinical Trials
- Date and Time: Monday, May 2,
2016, 11:00 AM-12:45 PM
- Room: Main Exhibit Hall
- Categories: AMD & CNV: Clinical &
Translational
Ocular Surface:
- Superior efficacy of Lastacaft® versus Pataday in grass- and
tree-allergic subjects
- Date and Time: Sunday, May 1,
2016, 8:30-10:15 AM
- Room: Main Exhibit Hall
- Categories: Allergic Conjunctivitis/Corneal Immunology
& Infection
- Clinical comparison of gel-type artificial tears
- Date and Time: Tuesday, May 3,
2016, 8:30-10:15 AM
- Room: Main Exhibit Hall
- Categories: Dry Eye II
- Randomized, controlled, crossover trial comparing the impact of
sham or intranasal neurostimulation on conjunctival goblet cell
degranulation
- Date and Time: Tuesday, May 3,
2016, 8:30-10:15 AM
- Room: Main Exhibit Hall
- Categories: Dry Eye II
- Effects of punctal occlusion on tear protein levels in dry eye
patients
- Date and Time: Tuesday, May 3,
2016, 12:00-12:15 PM
- Room: 606/607
- Categories: Dry Eye; Clinical & Epidemiology
- Definition and clinical characteristics of evaporative dry eye
in a general population of dry eye patients
- Date and Time: Thursday, May 5,
2016, 8:00-9:45 AM
- Room: Main Exhibit Hall
- Categories: Lacrimal Glands, Meibomian Glands &
Others
Glaucoma:
- Comparison of Burden of Care and Visual Field Progression
between Newly Diagnosed Glaucoma Patients Managed on Topical
Monotherapy and Those Who Switch or Add On Therapies
- Date and Time: Monday, May 2,
2016, 3:45-5:30 PM
- Room: Main Exhibit Hall
- Categories: Glaucoma
- A Multicenter Study Assessing Inter-Examiner Agreement of
Gonioscopic Shaffer Grading in Patients with Open-Angle Glaucoma
and/or Ocular Hypertension
- Date and Time: Tuesday, May 3,
2016, 8:30-10:15 AM
- Room: Main Exhibit Hall
- Categories: Glaucoma Clinical Studies/Pharmacology
- Additive ocular hypotensive effects of Bimatoprost
Sustained-Release intracameral implant on potent topical therapy in
monkeys
- Date and Time: Tuesday, May 3,
2016, 8:30-10:15 AM
- Room: Main Exhibit Hall
- Categories: Glaucoma Clinical Studies/Pharmacology
- Intracameral Administration of a Sustained Release Bimatoprost
Implant Efficiently Delivers Bimatoprost to Target Tissue Reducing
Risk of Topical Prostaglandin Analog- Associated Adverse Events
- Date and Time: Tuesday, May 3,
2016, 8:30-10:15 AM
- Room: Main Exhibit Hall
- Categories: Glaucoma Clinical Studies/Pharmacology
- Bimatoprost Sustained-Release Implants for Glaucoma Therapy:
12-Month Interim Results From a Phase 1/2 Clinical Trial
- Date and Time: Wednesday, May 4,
2016, 9:00-9:15 AM
- Room: 6A
- Categories: Glaucoma Clinical Studies
- A Quantitative Assessment of the Iridocorneal Angle in Asian
Patients with Open-angle Glaucoma or Ocular Hypertension Using
Schwalbe's Line-based Angle Biometrics
- Date and Time: Wednesday, May 4,
2016, 11:00 AM-12:45 PM
- Room: Main Exhibit Hall
- Categories: Glaucoma Imaging II
- Subsequent medical management of open-angle glaucoma patients
treated with laser trabeculoplasty
- Date and Time: Wednesday, May 4,
2016, 3:45-5:30 PM
- Room: Main Exhibit Hall
- Categories: Glaucoma Lasers, Surgery, & IOP
- Comparative Ocular Distribution of 14C-Latanoprost
Following a Single Intracameral or Repeated Topical Ocular Dose in
Dogs
- Date and Time: Wednesday, May 4,
2016, 3:45-5:30 PM
- Room: Main Exhibit Hall
- Categories: Glaucoma Potpourri
About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin,
Ireland, is a unique, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing innovative branded
pharmaceuticals, high-quality generic and over-the-counter
medicines and biologic products for patients around the
world.
Allergan markets a portfolio of best-in-class products that
provide valuable treatments for the central nervous system, eye
care, medical aesthetics, gastroenterology, women's health,
urology, cardiovascular and anti-infective therapeutic categories,
and operates the world's third-largest global generics business,
providing patients around the globe with increased access to
affordable, high-quality medicines. Allergan is an
industry leader in research and development, with one of the
broadest development pipelines in the pharmaceutical industry and a
leading position in the submission of generic product applications
globally.
With commercial operations in approximately 100
countries, Allergan is committed to working with
physicians, healthcare providers and patients to deliver innovative
and meaningful treatments that help people around the world live
longer, healthier lives.
For more information, visit Allergan's website
at www.allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing
trends and information as of the date of this release. Except as
expressly required by law, Allergan disclaims any intent
or obligation to update these forward-looking statements. Actual
results may differ materially from Allergan's current
expectations depending upon a number of factors
affecting Allergan's business. These factors include,
among others, the difficulty of predicting the timing or outcome
of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or
delays in manufacturing; and other risks and uncertainties detailed
in Allergan's periodic public filings with
the Securities and Exchange Commission, including but not
limited to Allergan's Annual Report on Form 10-K for the
year ended December 31, 2015 (certain of such periodic
public filings having been filed under the "Actavis plc" name).
Except as expressly required by law, Allergan disclaims any
intent or obligation to update these forward-looking
statements.
CONTACTS:
Investors:
Lisa DeFrancesco
(862) 261-7152
Media:
Mark Marmur
(973) 906-1526
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-presents-data-at-the-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting-in-seattle-300257241.html
SOURCE Allergan plc